175 related articles for article (PubMed ID: 36729147)
21. A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment.
Chen Z; Fang X; Huang H; Wang Z; Hong H; Chen M; Ren Q; Yao Y; Zhang L; Tian Y; Lin S; Lin T
Ann Hematol; 2020 Dec; 99(12):2811-2819. PubMed ID: 32975588
[TBL] [Abstract][Full Text] [Related]
22. Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yong W
Hematol Oncol; 2016 Jun; 34(2):61-8. PubMed ID: 25899032
[TBL] [Abstract][Full Text] [Related]
23. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
24. Atezolizumab in combination with intrathecal chemotherapy and radiation for treatment of isolated cerebral nervous system relapse in a patient with extranodal NK/T cell lymphoma: a case report.
Lipsitt AE; Hung JY; Langevin AM
J Med Case Rep; 2021 Mar; 15(1):102. PubMed ID: 33663601
[TBL] [Abstract][Full Text] [Related]
25. Primary pulmonary extranodal natural killer/T-cell lymphoma (ENKTL), nasal type: Two case reports and literature review.
Hu Q; Xu L; Zhang X; Wang J; Zhou Z
Medicine (Baltimore); 2020 Jun; 99(26):e20822. PubMed ID: 32590768
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological study of pulmonary extranodal nature killer/T-cell lymphoma, nasal type and literature review.
Ding W; Wang J; Zhao S; Yang Q; Sun H; Yan J; Gao L; Yao W; Zhang W; Liu W
Pathol Res Pract; 2015 Jul; 211(7):544-9. PubMed ID: 25953340
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
[No Abstract] [Full Text] [Related]
28. [Extranodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous breast involvement].
Fréling E; Granel-Brocard F; Serrier C; Ortonne N; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2015 Feb; 142(2):104-11. PubMed ID: 25554664
[TBL] [Abstract][Full Text] [Related]
29. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
30. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
[TBL] [Abstract][Full Text] [Related]
31. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
[TBL] [Abstract][Full Text] [Related]
32. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
[TBL] [Abstract][Full Text] [Related]
33. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
Fox CP; Civallero M; Ko YH; Manni M; Skrypets T; Pileri S; Kim SJ; Cabrera ME; Shustov AR; Chiattone CS; Horwitz SM; Dlouhy I; Spina M; Hitz F; Montoto S; Nagler A; Martinez V; De Souza CA; Fernandez-Alvarez R; Ballova V; Gabús R; Inghirami G; Federico M; Kim WS
Lancet Haematol; 2020 Apr; 7(4):e284-e294. PubMed ID: 32105608
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
Wei L; Wang J; Ye J; Yang L; Cong J; Li X; Wu Y; Cui X; Ding J; Yao N; Yang J
Leuk Lymphoma; 2020 Feb; 61(2):337-343. PubMed ID: 31517553
[TBL] [Abstract][Full Text] [Related]
35. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
[TBL] [Abstract][Full Text] [Related]
36. Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.
Xu QY; Yang HY; Li MW; He ZD; Hong HY; Peng ZG
Medicine (Baltimore); 2022 Sep; 101(38):e30731. PubMed ID: 36197207
[TBL] [Abstract][Full Text] [Related]
37. [A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].
Yuan F; Wei X; Yin Q; Li Y; Mi R; Ai H; Yang H; Li H; Ge S; Liu Y; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):614-8. PubMed ID: 25052604
[TBL] [Abstract][Full Text] [Related]
38. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
39. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
[TBL] [Abstract][Full Text] [Related]
40. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type.
Wang L; Wang H; Li PF; Lu Y; Xia ZJ; Huang HQ; Zhang YJ
Ann Hematol; 2015 Aug; 94(8):1381-8. PubMed ID: 25865943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
